Iovance Biotherapeutics vs Vericel
IOVA and VCEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IOVA and VCEL compare
Iovance Biotherapeutics is the larger company, worth 1.2 times as much as Vericel ($3.5B against $2.9B).
Iovance Biotherapeutics grew revenue faster over the last twelve months (51.3% versus 25.3% for Vericel).
Vericel keeps more of each dollar of sales as profit, with a net margin of 10.3% compared with −58.2% at Iovance Biotherapeutics.
Vericel scores higher on the StockData Score (15 against 9 for Iovance Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IOVA | VCEL |
|---|---|---|
| Size and price | ||
| Market cap | $3.5B | $2.9B |
| Share price | $7.76 | $56.96 |
| Change, 1 year | 206% | 40.9% |
| Change, 5 years | −58.8% | 28.5% |
| Beta (5Y) | 1.29 | 1.04 |
| Employees | 975 | 398 |
| StockData Score | ||
| Total score | 9 | 15 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 1 | 5 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 96.5× |
| P/S | 9.3× | 9.0× (better) |
| P/B | 4.3× (better) | 7.6× |
| EV/EBITDA | – | 67.7× |
| P/FCF | – | 50.4× |
| FCF yield | −6.1% | 2.0% (better) |
| Fair value | $4.47 | $16.74 |
| Margin of safety | −73.6% (better) | −240% |
| Growth | ||
| Revenue growth (TTM) | 51.3% (better) | 25.3% |
| Revenue growth, 5Y average | – | 17.3% |
| Net income growth (TTM) | – | 155% |
| EPS growth (TTM) | – | 211% |
| EPS growth, 5Y average | – | 39.8% |
| Profitability | ||
| Gross margin | 53.2% | 74.5% (better) |
| Operating margin | −60.8% | 8.3% (better) |
| Net margin | −58.2% | 10.3% (better) |
| FCF margin | −57.0% | 17.9% (better) |
| Return on equity | −29.1% | 9.4% (better) |
| Return on invested capital | −43.4% | 10.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | 42.0× |
| Current ratio | 5.20 (better) | 5.13 |
| Altman Z-score | 7.83 | 13.50 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | −8.3% | −0.26% (better) |
| Shareholder yield | −8.3% | −0.26% (better) |
| Ownership | ||
| Held by institutions | 63.3% | 108% |
| Held by insiders | 0.38% | 1.3% |
| Insider net buying, 12 months | – | −$13.0M |
| Short interest, % of float | 14.4% | 10.6% |
Go deeper
- IOVA stock overview
- IOVA income statement
- IOVA valuation and score
- VCEL stock overview
- VCEL income statement
- VCEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.